LGD-6972治疗2型糖尿病的Ⅰb期临床试验获较好结果
发布时间：2019-05-09 16:47
【摘要】：正配体制药公司宣布LGD-6972治疗2型糖尿病的Ⅰb期临床试验有较好的安全性、耐受性和药代动力学结果,证实其可剂量依赖性地降低空腹血糖。LGD-6972是胰高血糖素受体拮抗剂,能降低肝生成葡萄糖。试验表明,LGD-6972 5、10和15 mg是安全的且耐受良好。在血液、尿液、心电图和生命体征方面检测均未发现有临床意义的变化,无严重不良反应和停药者。副作用均为1~2级轻中度。随LGD-6972剂量增加,血药浓度呈线性升高,正常人与2型糖尿病患者的药代动力学参数相当,支持每日1次用药。LGD-6972能降低正
[Abstract]:The positive Ligand Pharmaceutical Company announced that the phase I b clinical trial of LGD-6972 in the treatment of type 2 diabetes mellitus has better safety, tolerance and pharmacokinetics results. It was confirmed that LGd-6972 was a glucagon receptor antagonist and decreased glucose production in the liver in a dose-dependent manner. The results showed that LGD-6972 5, 10 mg and 15 mg were safe and well tolerated. No clinical changes were found in blood, urine, electrocardiogram and vital signs, and there were no serious adverse reactions and withdrawal. The side effects were 1 鈮，
本文编号：2472934
[Abstract]:The positive Ligand Pharmaceutical Company announced that the phase I b clinical trial of LGD-6972 in the treatment of type 2 diabetes mellitus has better safety, tolerance and pharmacokinetics results. It was confirmed that LGd-6972 was a glucagon receptor antagonist and decreased glucose production in the liver in a dose-dependent manner. The results showed that LGD-6972 5, 10 mg and 15 mg were safe and well tolerated. No clinical changes were found in blood, urine, electrocardiogram and vital signs, and there were no serious adverse reactions and withdrawal. The side effects were 1 鈮，
本文编号：2472934
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2472934.html
最近更新
教材专著
